What are the recommended treatment options for refractory eczema that has not responded to optimized topical corticosteroids and calcineurin inhibitors?

Dupilumab is the First-Line Systemic Treatment for Refractory Eczema

For adults with atopic dermatitis refractory to optimized topical corticosteroids and calcineurin inhibitors, initiate dupilumab 600 mg subcutaneously at week 0, followed by 300 mg every 2 weeks. All guideline workgroup members surveyed favored dupilumab as the first-line systemic agent 1.

Treatment Algorithm for Refractory Disease

Step 1: Confirm True Refractory Disease

Before escalating to systemic therapy, verify that:

• Topical therapy has been truly optimized (adequate potency, appropriate application technique, sufficient duration)
• Alternative diagnoses have been excluded, particularly allergic contact dermatitis and cutaneous lymphoma 1
• Basic management including consistent emollient use is in place

Step 2: First-Line Systemic Therapy - Dupilumab

Dupilumab has the strongest evidence base with an excellent safety track record over 5+ years in clinical practice and no major emergent safety concerns 1. It targets the interleukin-4 receptor alpha and was the first FDA-approved targeted systemic treatment for atopic dermatitis.

Dosing:

• Loading dose: 600 mg subcutaneously
• Maintenance: 300 mg every 2 weeks 1

Key advantages:

• No laboratory monitoring required before initiation or during treatment 1
• Proven efficacy in improving signs, symptoms, and quality of life in large RCTs including 52-week trials 1
• Superior long-term safety profile compared to traditional immunosuppressants

Common pitfall - Conjunctivitis: This is the most common adverse event with dupilumab. For most patients, it is self-limited and managed conservatively with artificial tears. Refer to ophthalmology only if conjunctivitis is severe, persistent, or refractory to conservative measures 1.

Step 3: Alternative First-Line Options

The 2024 AAD guidelines provide strong recommendations for five agents 1:

Other biologics:

• Tralokinumab (IL-13 inhibitor): 600 mg at initiation, then 300 mg every 2 weeks. Somewhat less effective than dupilumab in network meta-analysis at 16 weeks, but similar safety profile 1
• Lebrikizumab (IL-13 inhibitor): FDA-approved in 2024 for moderate-to-severe disease 2

JAK inhibitors (oral):

• Upadacitinib 15 mg daily: Comparable efficacy to dupilumab standard dosing 1
• Abrocitinib and Baricitinib: Also carry strong recommendations 1

Important caveat: While JAK inhibitors show comparable or slightly superior short-term efficacy to dupilumab, they carry significant systemic risks and require careful patient selection 3. Dupilumab's superior long-term safety profile makes it the preferred first choice.

Step 4: Second-Line Systemic Options

The guidelines provide conditional recommendations in favor of these agents 1:

Phototherapy:

• Narrowband UVB (311 nm) preferred
• Consider when systemic therapy is contraindicated or patient preference

Traditional immunosuppressants:

• Cyclosporine: 3-5 mg/kg/day, most effective traditional agent but limited to short-term use (up to 1 year) due to toxicity concerns. Not FDA-approved for atopic dermatitis but approved for psoriasis 1
• Methotrexate: Conditional recommendation
• Azathioprine: Conditional recommendation
• Mycophenolate mofetil/mycophenolic acid: Conditional recommendation 1

Critical warning: The guidelines make a conditional recommendation AGAINST systemic corticosteroids for maintenance therapy 1. While they may have a limited role for occasional severe flares, they should never be considered for maintenance treatment until all other avenues have been explored 4.

Topical Therapy Continuation

Continue topical agents concurrently with phototherapy or systemic therapy for maintenance of response, rescue treatment, or flare management 1. This is standard practice and improves overall disease control.

Strength of Evidence Hierarchy

The 2024 AAD guidelines used GRADE methodology and provide the following hierarchy 1:

Strong recommendations (in order of preference based on workgroup consensus):

1. Dupilumab (unanimous first choice)
2. Tralokinumab
3. Upadacitinib
4. Abrocitinib
5. Baricitinib

Conditional recommendations in favor:

• Phototherapy
• Cyclosporine
• Methotrexate
• Azathioprine
• Mycophenolate

Conditional recommendation against:

• Systemic corticosteroids for maintenance

Special Considerations

For patients who fail or cannot tolerate dupilumab: Consider JAK inhibitors (upadacitinib, abrocitinib, or baricitinib) as the next option, recognizing their efficacy may be slightly higher but with greater systemic risks requiring careful monitoring 3.

Duration of treatment: Most RCT data are short-term (median 21-28 days), with extension studies providing longer-term data. The decision for long-term therapy should involve shared decision-making considering disease control, safety profile, and patient preferences 1.